Used in the development of therapeutics targeting the alternative complement pathway, particularly for treating diseases involving uncontrolled complement activation. Applied in research and drug formulation to inhibit Factor B, a key component in the complement cascade, thereby reducing inflammation and tissue damage in conditions such as age-related macular degeneration, atypical hemolytic uremic syndrome, and other autoimmune or inflammatory disorders. Also utilized as a reference standard in immunoassays and binding studies to evaluate the efficacy and specificity of anti-complement agents during preclinical and clinical development.